Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Product |
Terms/Details (Date) |
| | |||
Acorda Therapeutics Inc.* |
Rxpedite (joint venture between inChord Communications and Cardinal Health Inc.) |
Fampridine-SR |
Marketing agreement related to possible launch of sustained-release product; Rxpedite will manage all communications efforts (9/28) |
|
|||
Althea Technologies Inc.* |
Baxter Healthcare Corp. |
Co-promotion agreement for Althea's plasmid DNA manufacturing services and both firms' contract fill and finish services |
Althea will provide small batch services to customers through Phase III, and Baxter will service commercialization efforts (9/7) |
|
|||
BioMarin Pharmaceuticals Inc. (BMRN) |
Merck Eprova AG (subsidiary of Merck KGaA; Germany) |
Manufacturing and supply agreement for BioMarin's Phenoptin (6R-BH4), a drug nearing clinical trials for phenylketonuria |
BioMarin and Merck will share process development and manufacturing costs; Merck will supply product for clinical trials and would get royalties on commercial sales (11/20) |
|
|||
Cellectis SA* (France) |
Fermentas UAB (Lithuania) |
The endonuclease I-SceI |
Cellectis granted Fermentas a nonexclusive worldwide license for manufacturing and selling the endonuclease; terms were not disclosed (11/18) |
|
|||
FeRx Inc.* |
Laureate Pharma LLP |
MTC-DOX |
Laureate will provide fill and finishing services under the manufacturing agreement, terms of which were not disclosed (10/14) |
|
|||
Codexis Inc. (subsidiary of Maxygen Inc.; MAXY) |
Sandoz Inc. (unit of Novartis AG; Switzerland) |
Sandoz compound |
Collaboration to develop an improved process for manufacturing a Sandoz compound; Codex will get up-front and R&D funding, and potential milestone and royalty payments (10/27) |
|
|||
EraGen Biosciences Inc. Inc.* |
Itochu Corp. and CTC Laboratory Systems Corp. (both of Japan) |
EraGen's phylogenomics product, Master Catalog |
The two firms will exclusively distribute the product in Japan; terms were not disclosed (11/17) |
|
|||
Labopharm Inc. (Canada; TSE:DDS) |
CSC Pharmaceuticals Handels GmbH (Austria) |
Once-daily version of the analgesic tramadol |
Labopharm's European subsidiary granted GCS the right to market and sell the product in 14 Eastern European countries; Labopharm will supply product and earn a share of any revenues (11/6) |
|
|||
Nabi Biopharmaceuticals (NABI) |
Cambrex Corp. |
Manufacturing agreement for StaphVax vaccine |
Nabi granted Cambrex a 10-year renewable contract to manufacture the vaccine (10/9) |
|
|||
Ortec International Inc. (OTT BB:ORTN) |
Teva Pharmaceutical Industries Ltd. (Israel) |
OrCel tissue-engineered product |
Teva obtained a 10-year license to sell OrCel in Israel for wound healing and other dermatological applications; terms were not disclosed (10/23) |
|
|||
Viragen Inc. (AMEX:VRA) |
Pentafarma SA (Chile; subsidiary of Fresenius Medical Care) |
Distribution agreement for Viragen's Multiferon |
Pentafarma gained exclusive rights to sell the product in Chile; terms were not disclosed (11/17) |
|
|||
ZymoGenetics Inc. (ZGEN) |
Abbot Laboratories |
Recombinant human thrombin |
Abbott will be responsible for production of product for late-stage clinical studies and commercial sales; terms were not disclosed (10/2) |
|
|||
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE: Toronto Stock Exchange. | |||
